Axxion S.A.’s Edwards Lifesciences EW Stock Holding History

Axxion S.A.’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$398K	Buy	+4,400	New	+$369K	0.03%	254

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.7B AUM 13.92% 1-Year Est. Return

Axxion S.A.'s EW Position: Q2 2026 in Review

Axxion S.A. opened a new position in Edwards Lifesciences (EW) in Q2 2026: 4,400 shares worth $398K. The stake represents 0.03% of the portfolio and ranks #254 among its holdings.

1,246 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Axxion S.A. held 4,400 shares of Edwards Lifesciences worth $398K as of Q2 2026.
Edwards Lifesciences was a new Axxion S.A. position in Q2 2026.
Edwards Lifesciences made up 0.03% of Axxion S.A.'s portfolio in Q2 2026, its #254 holding.
1,246 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Axxion S.A.'s 13F filing for Q2 2026, filed 14 Aug 2026.